GRANTS FOR INNOVATION

The project is co-financed by the European Union from the European Regional Development Fund under the Operational Programme Innovative Economy

 

The project title : “Peptaderm”- development of a new drug candidate based on CLA derivative (4B8M)

 

Agreement number: UDA-POIG.01.04.00-10-028/09-00 UDA-POIG.04.01.00-10-028/09-00

 

Introduction

An important problem of transplantology – a dynamically developing area of modern-day medicine – is preventing a transplanted organ from being rejected by the recipient’s organism.

 

Immunosuppressive compounds, in restraining the immunological response, are drugs used not only for that purpose in transplantology but also for treating illnesses that have an autoimmunological foundation, particularly within dermatology.

 

The manufacture of such drugs is extremely expensive, and the drugs used most often, ciclosporin A, tacrolimus and rapamycin, all have undesirable side effects.

 

The search for new immunosuppressive compounds that are free of side effects and relatively cheap to produce, particularly in the group of natural peptide immunomodulators and their analogues, poses a serious challenge to medical chemistry.

 

Many scientific centres and pharmaceutical firms are carrying out tests on this on a broad scale.

 

Subject of the project

The aim of the project is to develop technology for producing medicines and putting them on the market.

The project is being carried out on the basis of a molecule which is an innovative chemical compound with immunosuppressive and anti-infection properties for use in dermatology.

 

The first tests carried out on animals suggest the possibility of using the this chemical compound to produce a drug that can be applied topically (cream, lotion) in allergic and seborrhoeic diseases of the skin such as atopic inflammation of the skin, psoriasis, various kinds of eczema, seborrhoeic inflammation of the skin, t-cell lymphoma skin forms, photoallergic changes and drug-induced skin reactions.

 

Generally speaking, it would seem that, because of the molecule’s strong anti-inflammatory properties, it will be used in all instances in which steroids are used topically today, but without their side effects.

 

Because of its very low toxicity it would appear that this will be a drug that can be used by children.